Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches
Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.
Central Imaging Review Analysis with mint Lesion - read-ready in minutes, not weeks
Watch in the video above a demonstration of our central imaging review software featuring a pre-configured, master trial workflow database designed to support your study requirements with read-ready functionality quickly available.
Multiple read paradigms: Support for single reads, double reads with adjudication, and eligibility workflows
Multi-criteria reads: Apply multiple evaluation frameworks to the same image
Flexible templates: Use standard response criteria read templates or custom eCRFs you design
Built-in analytics: Volumetrics, SUVs, tumor growth rates, and radiomics capabilities
Automated notifications: Alerts configured to align with your review flow
Export functionality: One-click exports for images, data (CDISC, radiomics, observations), and structured results
Related Resources
Related Resources
ESOI-EORTC Hands-On Workshop 2023
11/02
to
11/04/2023
MUNICH, GERMANY
Imaging in assessing response to cancer therapy – a hands-on course
University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy
A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…
RANZCR Brisbane 2023
10/19
to
10/21/2023
BRISBANE, AUSTRALIA
73rd Annual Scientific Meeting
About Cookies
This website uses cookies. Those have two functions: On the one hand they are providing basic functionality for this website. On the other hand they allow us to improve our content for you by saving and analyzing anonymized user data. You can redraw your consent to using these cookies at any time. Find more information regarding cookies on our Data Protection Declaration and regarding us on the Imprint.